top of page
Lab Experiments

Publications

The researchers at MPRG are among some of the most published in our particular field of expertise. Read on to explore a wide selection of our team’s most notable and groundbreaking papers and articles.

AWARD-WINNING PAPER

MPRG’s discovery of OAT3-mediated renal secretion of rivaroxaban has been incorporated in a verified PBPK model currently adopted by the Certara Simcyp Simulator. Based on this work published by the Drug Metabolism and Disposition (an ASPET journal) in 2019, Professor Eric Chan and his lab were awarded the Simcyp Academic Award 2020 under the category of Most Informative Scientific Report.

​

EJY Cheong, DWY Teo, DXY Chua and ECY Chan. Systematic development and verification of a physiologically-based pharmacokinetic model of rivaroxaban. Drug Metabolism and Disposition 47 (November 2019) 1291-1306 DOI: 10.1124/dmd.119.086918

DMD_GA5.tif
IMPACTFUL PAPER
(featured on cover page)

Using knowledge gleaned from the MBI of cardiac CYP2J2 by dronedarone, MPRG innovated and patented a small molecule drug candidate, termed as poyendarone, for the safe and efficacious treatment of atrial fibrillation without the adverse effects associated with dronedarone and amiodarone. This discovery of poyendarone was published by the Acta Pharmaceutica Sinica B (IF: 14.9) and featured as the cover story in the October 2022 issue.

​

A Karkhanis, G Venkatesan, R Kambayashi, JWH Leow, MQ Han, H Izumi-Nakaseko, A Goto, JKS Pang, BS Soh, P Kojodjojo, A Sugiyama and ECY Chan*. Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts. Acta Pharmaceutica Sinica B 12 (October 2022) 3905-3923 DOI:10.1016/j.apsb.2022.03.008

IMPACTFUL PAPER
(translated to real-world application)

Using their DMPK expertise, MPRG scientists made significant contribution to forensic science research especially in the development of urinary biomarkers for detecting the consumption of novel synthetic cannabinoids. Using both bottom-up in vitro and top-down in vivo techniques, MPRG established a urinary biomarker database for the screening of illicit abuse of synthetic cannabinoids by the toxicological laboratory of the Health Science Authority of Singapore (HSA).

​​

KZH Lee, Z Wang, CY Fong, EML Goh, HY Moy and ECY Chan*. Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZOPOXIZID and BZO-CHMOXIZID for Illicit Abuse Monitoring. Clinical Chemistry 68 (November 2022) 1436–1448 DOI: 10.1093/clinchem/hvac138  Faculty of Science Research News 

20221005_ST Op-Ed Article on Synthetic Cannabis_edited.jpg

2024

  1. LX Qian, ZT Wang, MF Paine, ECY Chan*, Z Zhou*. Application of Pharmacokinetic Modeling and Simulation to Inform Dosing Decisions for Geriatric Patients. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology (September 2024) In Press

  2. ZT Wang, KHY Luk, EJY Cheong, SM Tham, R Periaswami, PC Toh, ZT Wang, QH Wu, WC Tsang, A Kesavan, ASC Wong, PT Wong, F Lim, E Chiong*, ECY Chan*. Characterization and prediction of OATP1B activity in prostate cancer patients on abiraterone acetate using endogenous biomarker coproporphyrin I. Drug Metabolism and Disposition (August 2024) In Press

  3. DZW Ng, A Low, AJH Tan, JH Ong, WT Kwa, JWJ Lee, ECY Chan*. Ex vivo metabolism kinetics of primary to secondary bile acids via a physiologically relevant human faecal microbiota model. Chemico-Biological Interactions 399 (August 2024) 111140 - 111148 DOI: https://doi.org/10.1016/ 

  4. JWH Leow and ECY Chan*. CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control. Pharmacology & Therapeutics 258 (June 2024) 108637 - 108658 DOI:10.1016/j.pharmthera.2024.108637 

  5. ​SB Liu*, SY Zhao, XX Zhang, ECY Chan, ZT Wang, H Li, X Tian*. Identification of the human Cytochrome P450 enzymes (P450s) responsible for metabolizing infigratinib to its pharmacologically active Metabolites, BHS697, and CQM157, and assessment of their in vitro inhibition of P450s and UDP-glucuronosyltransferases (UGTs). Biochemical Pharmacology 226 (June 2024) 116390 - 116422 DOI: https://doi.org/10.1016/

  6. SM Ong, DZW Ng, TEZ Chee, AA Sng, CK Heng, YS Lee, ECY Chan, DSQ Ooi*. Plasma fatty acid esters of hydroxy fatty acids and surrogatefatty acid esters of hydroxy fatty acids hydrolysis activity inchildren with or without obesity and in adults with or withoutcoronary artery disease. Diabetes, Obesity and Metabolism (May 2024) DOI: https://doi.org/10.1111/

  7. TM Ng, ZT Wang and ECY Chan*. Physiologically-based Pharmacokinetic Modelling Guided Dose Evaluations for Nirmatrelvir/Ritonavir in Renal Impairment for the Management of COVID-19. British Journal of Clinical Pharmacology (April 2024) DOI: https://doi.org/10.1111/bcp.16074

  8. W Wei, LWT Tang, RK Verma, ZT Wang, H Fan* and ECY Chan*. Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F–F′ Loop Perturbations. Journal of Chemical Information and Modeling 64 (March 2024) 2058 - 2067 DOI: 10.1021/acs.jcim.3c01837

  9. L Hou, YY Zhao, SY Zhao, XX Zhang, X Yao, JJ Yang, ZT Wang, ECY Chan, SB Liu*. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19. Chemico-Biological Interactions 387 (January 2024) 110811 - 110816  DOI: 10.1016/j.cbi.2023.110811 

2023

  1. L Wojciech, CW Png, EY Koh, DYQ Kioh, L Deng, ZT Wang, LZ Wu, M Hamidinia, DWH Tung, W Zhang, S Pettersson, ECY Chan, YL Zhang, KSW Tan, NRJ Gascoigne* A tryptophan metabolite made by a gut microbiome eukaryote induces pro-inflammatory T cells The EMBO Journal 42 (September 2023) e112963 DOI: 10.15252/embj.2022112963

  2. YX Gu, X Li, ECY Chan*. Risk assessment of cultured meat. Trends in Food Science and Technology 138 (August 2023) 491-499 DOI: 10.1016/j.tifs.2023.06.037

  3. JWH Leow, YX Gu, ECY Chan*. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes. European Journal of Pharmaceutical Sciences 187 (August 2023) 106475 - 106487 DOI: 10.1016/j.ejps.2023.106475

  4. DZW Ng, SXY Lee, DSQ Ooi, LDH Ta, GC Yap, CJX Tay, CH Huang, EWH Tham, EXL Loo, LPC Shek, A Goh, HPSV Bever, OH Teoh, YS Lee, F Yap, KH Tan, YS Chong, SY Chan, JG Eriksson, KM Godfrey, BW Lee, ECY Chan*. Sensitive LC-MS/MS method for the temporal profiling of bile acids, fatty acids and branched-chain alpha-keto acids in maternal plasma during pregnancy and cord blood plasma at delivery. Clinical Chimica Acta 547 (July 2023) 117449 - 117459 DOI: 10.1016/j.cca.2023.117449

  5. EJY Cheong, SY Chin, ZW Ng, TJ Yap, EZB Cheong, ZT Wang, ECY Chan*. Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement. Clinical Pharmacokinetics 62 (July 2023) 1243 - 1261 DOI: 10.1007/s40262-023-01266-y

  6. JWH Leow, XJ Ang and ECY Chan*. Development and verification of a physiologically-based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: application to prospective simulation of complex drug-drug interaction with rivaroxaban. British Journal of Clinical Pharmacology 89 (June 2023) 1873 - 1890 DOI: 10.1111/bcp.15670 

  7. Z Wang and ECY Chan*. Role of Cytochrome P450 2C8 in Drug-Drug Interaction between Amiodarone and Nirmatrelvir/Ritonavir via Physiologically-Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics 113 (June 2023) DOI: 10.1002/cpt.2885

  8. K Tan, L Deng, L Wojciech, CW Png, DYQ Kioh, ECY Chan, Y Zhang, N Gascoigne, and GC Ng*. Colonization with ubiquitous protist Blastocystis ST1 ameliorates DSS-induced colitis and promotes beneficial microbiota and immune outcomes. npj Biofilms and Microbiomes 9 Article number: 22 (2023) (April 2023) DOI:10.1038/s41522-023-00389-1 

  9. J Lin, SY Chin, SPF Tan, HC Koh, EJY Cheong, ECY Chan and JCY Chan*. Mechanistic Middle-Out Physiologically-Based Toxicokinetic Modeling of Transporter-Dependent Disposition of Perfluorooctanoic Acid. Environmental Science & Technology 57 (April 2023) 6825 -6834  DOI: 10.1021/acs.est.2c05642 

  10. LDH Ta, JCY Chan, GC Yap, CH Huang, EH Tham, EXL Loo, NHA Suaini, LPC Shek, N Karnani, A Goh, HPS Van Bever, OH Teoh, YH Chan, C Lay, J Knol, F Yap, KH Tan, YS Chong, MFF Chong, SY Chan, JG Eriksson, KM Godfrey, ECY Chan* and BW Lee*. Prenatal Diet, Plasma Micronutrients/Metabolome And Inflammatory Status Influence The Development Of Atopic Eczema In Early Childhood. Allergy 78 (March 2023) 867 - 871 DOI: 10.1111/all.15573 

  11. Y Gu, H Chen, X Li, D Li, Y Sun, L Yang, Y Ma* and ECY Chan*. Lactobacillus paracasei IMC 502 ameliorate type 2 diabetes by mediating gut microbiota-SCFAs-hormone/inflammation pathway in mice. Journal of the Science of Food and Agriculture 103 (March 2023) 2949 – 2959 DOI: 10.1002/jsfa.12267 

  12. L Deng, L Wojciech, CW Png, DYQ Kioh, Y Gu, TT Aung, B Malleret, ECY Chan, G Peng, Y Zhang, NRJ Gascoigne and KSW Tan*. Colonization with two different Blastocystis subtypes in DSS-induced colitis mice is associated with strikingly different microbiome and pathological features. Theranostics 13 (February 2023) 1165 - 1179 DOI: 10.7150/thno.81583 

2022

  1. LWT Tang and ECY Chan*. Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation. Biochemical Pharmacology  206 (December 2022) 115336 - 115348 DOI: 10.1016/j.bcp.2022.115336

  2. KZH Lee, Z Wang, CY Fong, EML Goh, HY Moy and ECY Chan*. Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZOPOXIZID and BZO-CHMOXIZID for Illicit Abuse Monitoring. Clinical Chemistry 68 (November 2022) 1436 – 1448 DOI: 10.1093/clinchem/hvac138  Faculty of Science Research News  

  3. ZT Wang and ECY Chan*. Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment. Clinical Pharmacology &  Therapeutics 112 (October 2022) 803 - 807 DOI: 10.1002/cpt.2687

  4. A Karkhanis, G Venkatesan, R Kambayashi, JWH Leow, MQ Han, H Izumi-Nakaseko, A Goto, JKS Pang, BS Soh, P Kojodjojo, A Sugiyama and ECY Chan*. Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts. Acta Pharmaceutica Sinica B 12 (October 2022) 3905 - 3923 DOI:10.1016/j.apsb.2022.03.008

  5. LWT Tang, G Wu and ECY Chan*. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban. Journal of Pharmacology and Experimental Therapeutics 382 (August 2022) 123 - 134 DOI: 10.1124/jpet.122.001222

  6. ZT Wang and ECY Chan*. Physiologically Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics. Clinical Pharmacology & Therapeutics 112 (August 2022) 291 - 296 DOI: 10.1002/cpt.2600 

  7. LWT Tang, J Fu, SW Koh, G Wu, L Zhou and ECY Chan*. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of Cytochrome P450 3A. Drug Metabolism and Disposition 50 (July 2022) 931 - 941 DOI: 10.1124/dmd.122.000895

  8. Y Gu, X Li, H Chen, Y Sun, L Yang, Y Ma and ECY Chan*. Antidiabetic effects of multi-species probiotic and its fermented milk in mice via restoring gut microbiota and intestinal barrier. Food Bioscience 47 (June 2022) 101619 - 10130 DOI: 10.1016/j.fbio.2022.101619

  9.  SX Soh*, SYD Tan and ECY Chan. Simvastatin, but not Atorvastatin, is associated with higher peak Rivaroxaban serum levels and bleeding: An Asian cohort study from Singapore. Cardiovascular Drugs and Therapy 37 (May 2022) 917–925 DOI: 10.1007/s10557-022-07346-8 

  10. LWT Tang and ECY Chan*. Quantification of the Irreversible Fibroblast Growth Factor Receptor Inhibitor Futibatinib by UPLC-MS/MS: Application to the Metabolic Stability Assay in Human Liver Microsomes for the Estimation of its In Vitro Hepatic Intrinsic Clearance. Journal of Pharmaceutical and Biomedical Analysis 214 (May 2022) 114731 - 114738 DOI:10.1016/j.jpba.2022.114731 

  11. LWT Tang, W Wei,  RK Verma, SK Koh, L Zhou, H Fan and ECY Chan*. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminate in Mechanism-Based Inactivation of Cytochrome P450 3A. Drug Metabolism and Disposition 50 (May 2022) 529 - 540 DOI: 10.1124/dmd.121.000804

  12. EJY Cheong, DZW Ng, SY Chin, Z Wang and ECY Chan*. Application of a PBPK Model of Rivaroxaban to Prospective Simulations of Drug-Drug-Disease Interactions with Protein Kinase Inhibitors in CA-VTE. British Journal of Clinical Pharmacology 88 (May 2022) 2267 – 2283 DOI: 10.1111/bcp.15158

  13. HY Cheng, JCY Chan,  GC Yap, CH Huang, DYQ Kioh, EH Tham, EXL Loo, LPC Shek, N Karnani, A Goh, HPS Van Bever, OH Teoh, YH Chan, C Lay, J Knol, F Yap, KH Tan, YS Chong, K Godfrey, ECY Chan, BW Lee and LDH Ta*. Evaluation of stool short chain fatty acids profiles in the first year of life with childhood atopy-related outcomes. Frontiers In Allergy 3 (April 2022) 873168 - 873177 DOI: 10.3389/falgy.2022.873168

  14. LWT Tang, YRR Lim, G Venkatesan and ECY Chan*. Rational Deuteration of Dronedarone Attenuates its Toxicity in Human Hepatic HepG2 Cells. Toxicology Research 11 (April 2022) 311 – 324 DOI: 10.1093/toxres/tfac017

  15. L Deng, L Wojciech, CW Png, EYL Koh, TT Aung, DYQ Kioh, ECY Chan, B Malleret, Y Zhang, G Peng, N Gascoigne and KSW Tan*. Experimental colonization with Blastocystis ST4 is associated with protective immune responses and modulation of gut microbiome in a DSS-induced colitis mouse model. Cellular and Molecular Life Sciences 79 (April 2022) Article number: 245 (2022) DOI: 10.1007/s00018-022-04271-9

  16. LWT Tang, TWH Cheong and ECY Chan*. Febuxostat and its Major Acyl Glucuronide Metabolite are Potent Inhibitors of Organic Anion Transporter 3: Implications for Drug-Drug Interactions with Rivaroxaban. Biopharmaceutics & Drug Disposition 43 (April 2022) 57 – 65 DOI: 10.1002/bdd.2310

  17. S Liu*, Z Wang, ECY Chan, Y Zhao, J Kang, X Zhang and X Tian*. Inhibition of Cytochrome P450 Enzymes and Uridine 5′-diphospho-glucuronosyltransferases by Vicagrel in Human Liver Microsomes: A Prediction of Potential Drug-Drug Interactions. Chemico-Biological Interactions 352 (January 2022) 109775  - 109784 DOI:10.1016/j.cbi.2021.109775 

2021

  1. C Wilder-Smith, SH Lee, SS Olesen, JY Low, DYQ Kioh, R Ferraris, A Materna  and ECY Chan*. Fructose intolerance is not associated with malabsorption in patients with functional gastrointestinal disorders. Neurogastroenterology and Motility 33; e14150  (December 2021)  DOI: 10.1111/nmo.14150 

  2. CH Sia, Z Wang, EML Goh, YL Tan, CY Fong, HY Moy and ECY Chan*. Urinary Metabolite Biomarkers for the Detection of ADB-BUTINACA Abuse. Clinical Chemistry 67 (November 2021) 1534 - 1544 DOI: 10.1093/clinchem/hvab134 Faculty of Science Research News 

  3. ZT Wang, CY Fong, EML Goh, HY Moy and ECY Chan*. Transesterification of indazole-3-carboxamide synthetic cannabinoids: Identification of metabolite biomarker for diagnosing co-abuse of 5F-MDMB-PINACA and alcohol. Journal of Analytical Toxicology 46 (November 2021) 1016 - 1024 DOI: 10.1093/jat/bkab121 

  4. ZT Wang, EJY Cheong, P Kojodjojo and ECY Chan*. Model-based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population. Cardiovascular Drugs and Therapy (October 2021) 605 - 609 DOI: 10.1007/s10557-021-07266-z

  5. LWT Tang, JW Teng, RK Verma, SK Koh, L Zhou, ML Go, H Fan and ECY Chan*. Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P450 3A4. Drug Metabolism and Disposition 49 (September 2021) 856 - 858 DOI: 10.1124/dmd.121.000508 

  6. LWT Tang,  RK Verma, RP Yong, X Li, L Wang, Q Lin, H Fan and ECY Chan*. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450 3A4 and 3A5. Molecular Pharmacology 100 (September 2021) 224 - 236 DOI: 10.1124/molpharm.121.000256  

  7. JWH Leow, RK Verma, ABH Lim, H Fan and ECY Chan*. Atypical kinetics of cytochrome P450 2J2: epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors. European Journal of Pharmaceutical Sciences 164 (September 2021) 105889 DOI: 10.1016/j.ejps.2021.105889

  8. A Karkhanis,  ECY Chan and EC Ren*. Preliminary discovery of novel markers for human cell line activation test (h-CLAT). Toxicology in Vitro 74 (August 2021) 105154 DOI: 10.1016/j.tiv.2021.105154 

  9. LWT Tang, JW Teng, SK Koh, L Zhou, ML Go and ECY Chan*. Mechanism-based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib. Chemical Research in Toxicology 34 (July 2021) 1800 - 1813 DOI: 10.1021/acs.chemrestox.1c00178 

  10. R Kambayashi, A Goto, Y Nunoi, M Hagiwara-Nagasawa, H Izumi-Nakaseko, G Venkatesan, Y Takei, A Matsumoto, ECY Chan* and A Sugiyama*. An exploratory analysis of effects of poyendarone, a deuterated analogue of dronedarone, on the canine model of paroxysmal atrial fibrillation. Naunyn-Schmiedeberg’s Archives of Pharmacology 394 (June 2021) 1103 - 1102 DOI: 10.1007/s00210-020-02047-1

  11. HL Tan, LWT Tang, SY Chin and ECY Chan*. Investigation of the Arcane Inhibition of Human Organic Anion Transporter 3 by Benzofuran Antiarrhythmic Agents. Drug Metabolism and Pharmacokinetics 38 (June 2021) 100390 DOI: 10.1016/j.dmpk.2021.100390 

  12. SH Lee, R Mahendran, SM Tham, TP Thamboo, BJ Chionh, YX Lim, WC Tsang, QH Wu, JY Chia, MHW Tay, BYS Goh, KW Chen, JZ Mallan, R Periaswami, L Rata, SN Choo,  DYQ Kioh, E Chiong, K Esuvaranathan and ECY Chan*. Tryptophan/kynurenine ratio as biomarker of bladder cancer. BJU International 127 (April 2021) 445 - 453 DOI: 10.1111/bju.15205

  13. SPF Tan, ECY Chan and JCY Chan*. Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model. Alternatives To Animal Experimentation 38 (April 2021) 253 – 268 DOI: 10.14573/altex.2007151

  14. LWT Tang, RK Verma, H Fan and ECY Chan*. Mechanism-based Inactivation of Cytochrome P450 3A4 by Benzbromarone. Molecular Pharmacology 99 (April 2021) 266 - 276 DOI: 10.1124/molpharm.120.000086

  15. W Lie,  EJY Cheong, EML Goh, HY Moy, A Cannaert, CP Stove and ECY Chan*. Diagnosing intake and rationalizing toxicities associated with 5F-MDMB-PINACA and 4F-MDMB-BINACA abuse. Archives of Toxicology 95 (February 2021) 489 - 508 DOI: 10.1007/s00204-020-02948-3 Faculty of Science Research News

2020

  1. SH Lee, R Mahendran, SM Tham, TP Thamboo, DYQ Kioh, LWT Tang, E Chiong, K Esuvaranathan and ECY Chan*. Combination Bacillus Calmette–Guérin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer. BJU International 126 (November 2020) 554-556 DOI: 10.1111/bju.15201

  2. LDH Ta, JCY Chan, GC Yap, RW Purbojati, DI Drautz-Moses, YM Koh, CJX Tay, CH Huang, DYQ Kioh, JY Woon, EH Tham, EXL Loo, LPC Shek, N Karnani, A Goh, HPS Van Bever, OH Teoh, YH Chan, C Lay, J Knol, F Yap, KH Tan, YS Chong, KM Godfrey, S Kjelleberg, SC Schuster, ECY Chan* and BW Lee*. A Compromised Developmental Trajectory of the Infant Gut Microbiome and Metabolome in Atopic Eczema. Gut Microbes 12 (October 2020) 1-12 DOI: 10.1080/19490976.2020.1801964 

  3. EJY Cheong, PC Nair, RWY Neo, HT Tu, F Lin, E Chiong, K Esuvaranathan, H Fan, RZ Szmulewitz, CJ Peer, WD Figg, CLL Chai, JO Miners and ECY Chan*. Slow and tight binding inhibition of CYP17A1 by abiraterone redefines its kinetic selectivity and dosing regimen. The Journal of Pharmacology and Experimental Therapeutics 374 (September 2020) 438-451 DOI: 10.1124/jpet.120.265868 Faculty of Science Research News

  4. L Zhou, JCY Chan, S Chupin, N Gueguen, V Desquiret-Dumas, SK Koh, J Li, Y Gao, L Deng, C Verma, RW Beuerman, ECY Chan, D Milea* and P Reynier*. Increased protein S-Glutathionylation in Leber’s Hereditary Optic Neuropathy (LHON). International Journal of Molecular Sciences 21 (April 2020) 3027 DOI: 10.3390/ijms21083027

  5. R Kambayashi, M Hagiwara-Nagasawa, Y Kondo, ZJ Yeo, A Goto, K Chiba, Y Nunoi, H Izumi-Nakaseko, JWH Leow, G Venkatesan, A Matsumoto, ECY Chan* and A Sugiyama*. How the deuteration of dronedarone can modify its cardiovascular profile: in vivo characterization of electropharmacological effects of poyendarone, a deuterated analogue of dronedarone. Cardiovascular Toxicology 20 (January 2020) 339-350 DOI: 10.1007/s12012-019-09559-0

2019

  1. EJY Cheong, DWY Teo, DXY Chua and ECY Chan. Systematic development and verification of a physiologically-based pharmacokinetic model of rivaroxaban. Drug Metabolism and Disposition 47 (November 2019) 1291-1306 DOI: 10.1124/dmd.119.086918

  2. JCY Chan, SPF Tan, Z Upton and ECY Chan. Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing. Alternatives To Animal Experimentation 36 (October 2019) 597-612 DOI: 10.14573/altex.1812051

  3. S Haldar, SC Chia, SH Lee, J Lim, MKS Leow, ECY Chan and CJ Henry*. Polyphenol-rich curry made with mixed spices and vegetables benefits glucose homeostasis in Chinese males (Polyspice Study): a dose–response randomized controlled crossover trial. European Journal of Nutrition 58 (February 2019) 301-303 DOI: 10.1007/s00394-017-01594-9

2018

  1. L Chen, Y Gao, LZ Wang, N Cheung, GSW Tan, CMG Cheung, RW Beuerman, TY Wong, ECY Chan* and L Zhou*. Recent advances in the applications of metabolomics in eye research. Analytica Chimica Acta 1037 (December 2018) 28 – 40. DOI: 10.1016/j.aca.2018.01.060z

  2. JCY Chan, ACK Soh, DYQ Kioh, J Li, C Verma, SK Koh, RW Beuerman, L Zhou* and ECY Chan*. Reactive metabolite-induced protein glutathionylation: a potentially novel mechanism underlying acetaminophen hepatotoxicity. Molecular & Cellular Proteomics 17 (October 2018) 2034 – 2050 DOI: 10.1074/mcp.RA118.000875 Faculty of Science Research News

  3. S Haldar, SH Lee, JJ Tan, SC Chia, CJ Henry* and ECY Chan*. Dose-dependent increase in unconjugated cinnamic acid concentration in plasma following consumption of polyphenol rich curry in polyspice study. Nutrients 10 (July 2018) 934 DOI: 10.3390/nu10070934

  4. A Karkhanis,  JWH Leow, T Hagen and ECY Chan*. Dronedarone-induced cardiac mitochondrial dysfunction and its mitigation by epoxyeicosatrienoic acids. Toxicological Sciences 163 (May 2018) 79 – 91 DOI: 10.1093/toxsci/kfy011

  5. EJY Cheong, JJN Goh, Y Hong, P Kojodjojo and ECY Chan*. Rivaroxaban with and without amiodarone in renal impairment. Journal of the American College of Cardiology 71 (March 2018) 1395 – 1397 DOI: 10.1016/j.jacc.2018.01.044

  6. LC Phua, S Goh, DWM Tai, WQ Leow, SMFB Syed Abdillah Al, CY Chan, JH Kam, TKH Lim and ECY Chan*. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemotherapy and Pharmacology 81 (February 2018) 277 – 289. DOI: 10.1007/s00280-017-3475-6

  7. LY Yip, CC Aw, SH Lee, YS Hong, HC Ku, WH Xu, JMX Chan, EJY Cheong, KR Chng, AHQ Ng, N Nagarajan, R Mahendran, YK Lee, ER Browne and ECY Chan*. The liver-gut microbiota axis modulates hepatotoxicity of tacrine of the rat. Hepatology 67 (January 2018) 282 – 295. DOI: 10.1002/hep.29327  Faculty of Science Research News 

2017

  1. A Karkhanis, NDT Tram and ECY Chan*. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids. Biochemical Pharmacology 146 (December 2017) 188 – 198. DOI: 10.1016/j.bcp.2017.09.012

  2. RH Ho, JCY Chan, F Hao, DYQ Kioh, BW Lee* and ECY Chan*. In silico and In vitro interactions between short chain fatty acids and human histone deacetylases. Biochemistry 56 (September 2017) 4871 – 4878. DOI: 10.1021/acs.biochem.7b00508

  3. JCY Chan, DYQ Kioh, GC Yap, BW Lee* and ECY Chan*. A novel LCMSMS method for quantitative measurement of short-chain fatty acids in human stool derivatized with 12C- and 13C-labelled aniline. Journal of Pharmaceutical and Biomedical Analysis 138 (May 2017) 43 – 53. DOI: 10.1016/j.jpba.2017.01.044

  4. Q Chen, C Li, Z Gong, ECY Chan, SA Snyder and SH Lam*. Common deregulated gene expression profiles and morphological changes in developing zebrafish larvae exposed to environmental-related high to low concentrations of glucocorticoids. Chemosphere. 172 (April 2017) 429 – 439. DOI: 10.1016/j.chemosphere.2017.01.036

  5. EJY Cheong, JJN Goh, Y Hong, G Venkatesan, Y Liu, GNC Chiu, P Kojodjojo and ECY Chan*. Application of static modeling in the prediction of in vivo drug-drug interactions between rivaroxaban and anti-arrhythmic agents based on in vitro inhibition studies. Drug Metabolism and Disposition 45 (March 2017) 260 – 268. DOI: 10.1124/dmd.116.073890

  6. P Bahety, THV Nguyen, Y Hong, L Zhang, ECY Chan* and PL Ee*.Understanding the cholesterol metabolism-perturbing effects of docosahexaenoic acid by gas chromatography-mass spectrometry targeted metabonomic profiling. European Journal of Nutrition 56 (February 2017) 29 – 43. DOI: 10.1007/s00394-015-1053-4

  7. JCY Chan, PS Ong, P Lim, PXL Teng and ECY Chan*. Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells. Cancer Chemotherapy and Pharmacology 79 (January 2017) 117 – 130. DOI: 10.1007/s00280-016-3211-7

  8. YY Cai, TP Lim, J Teo, S Suranthran, ECY Chan, Y Hong, W Lee, TY Tan, TT Tan, TS Koh, LY Hsu and AL Kwa*. Evaluating polymyxin-B-based combinations against carbapenem-resistant Escherichia coli in time-kill studies and in a hollow-fiber infection model. Antimicrobial Agents and Chemotherapy 61 (January 2017) e01509 – e01516. DOI: 10.1128/AAC.01509-16

2016

  1. YY Cai, TP Lim, J Teo, S Suranthran, W Lee, Y Hong, ECY Chan, TY Tan, TH Koh, HL Yang and AL Kwa*. In vitroActivity of Polymyxin B in combination with various antibiotics against extensively resistant Enterobacter cloacae with decreased susceptibility to Polymyxin B. Antimicrobial Agents and Chemotherapy 60 (September 2016) 5238 – 5246. DOI: 10.1128/AAC.00270-16

  2. YY Pang, YM Tan, ECY Chan and HK Ho*. Phase I metabolic stability and electrophilic reactivity of 2-phenylaminophenylacetic acid derived compounds. Chemical Research in Toxicology 29 (July 2016) 1118 – 1131. DOI: 10.1021/acs.chemrestox.6b00042

  3. A Karkhanis, HY Lam, G Venkatesan, SK Koh, CLL Chai, L Zhou, Y Hong, P Kojodjojo and ECY Chan*. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites. Biochemical Pharmacology 107 (May 2016) 67 – 80. DOI: 10.1016/j.bcp.2016.03.005 Faculty of Science Research News

  4. LY Chen, CY Cheng, H Choi, MK Ikram, C Sabanayagam, GSW Tan, D Tian, L Zhang, G Venkatesan, ES Tai, JJ Wang, P Mitchell, CMG Cheung, RW Beuerman, L Zhou*, ECY Chan* and TY Wong. Plasma Metabonomic Profiling of Diabetic Retinopathy. Diabetes 65 (April 2016) 1099 – 1108. DOI: 10.2337/db15-0661 Faculty of Science Research News

  5. C Li, P Li, YM Tan, SH Lam, ECY Chan and Z Gong*. Metabolomic characterization of liver injury caused by acute arsenic toxicity in zebrafish. PLOS ONE (March 2016) DOI: 10.137/journal.pone.0151225

  6. Y Hong, YMF Chia, RH Yeo, G Venkatesan, SK Koh, CLL Chai, L Zhou, P Kojodjojo and ECY Chan*. Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone. Molecular Pharmacology 89 (January 2016) 1 – 13. DOI: 10.1124/mol.115.100891

2015 - 2010

  1. JCY Chan, L Zhou and ECY Chan*. The Isotope-Coded Affinity Tag Method for Quantitative Protein Profile Comparison and Relative Quantitation of Cysteine Redox Modification. Current Protocols in Protein Science 82 (November 2015) 23.2.1 – 23.2.19. DOI: 10.1002/0471140864.ps2302s82

  2. LC Phua, CH Wilder-Smith, YM Tan, T Gopalakrishnan, RK Wong, X Li, ME Kan, J Lu, A Keshavarzian and ECY Chan*. Gastrointestinal symptoms and altered intestinal permeability induced by combat-training are associated with distinct metabotypic changes. Journal of Proteome Research 14 (October 2015) 4734 – 4742. DOI: 10.1021/acs.jproteome.5b00603

  3. LY Yip and ECY Chan*. Investigation of Host-Gut Microbiota Modulation of Therapeutic Outcome. Drug Metabolism and Disposition 43 (October 2015) 1619 – 1631. DOI: 10.1124/dmd.115.063750

  4. WYB Foo, HY Tay, ECY Chan and AJ Lau*. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A. Biochemical Pharmacology 97 (October 2015) 320 – 330. DOI: 10.1016/j.bcp.2015.07.036

  5. LC Phua, HW Ng, AHL Yeo, E Chen, MSM Lo, PY Cheah, ECY Chan, PK Koh* and HK Ho*. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian metastatic colorectal cancer patients. Oncology Letters 10 (October 2015) 2519 – 2526. DOI: 10.3892/ol.2015.3560

  6. LY Chen, J Li, T Guo, S Ghosh, SK Koh, D Tian, L Zhang, D Jia, RW Beuerman, R Aebersold, ECY Chan*, L Zhou*. Global metabonomic and proteomic analysis of human conjunctival epithelial cells (IOBA-NHC) in response to hyperosmotic stress. Journal of Proteome Research 14 (August 2015) 3982 – 3995. DOI: 10.1021/acs.jproteome.5b00443

  7. TP Lim, YY Cai, Y Hong, ECY Chan, S Suranthran, J Teo, W Lee, TY Tan, LY Hsu, TH Koh, TT Tan and AL Kwa*. In-vitro Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 59 (May 2015) 2515 – 2524. DOI: 10.1128/AAC.03639-14

  8. ECY Chan*, KK Pasikanti, Y Hong, PC Ho, R Mahendran, LRN Mani, E Chiong and K Esuvaranathan*. Metabonomic profiling of bladder cancer. Journal of Proteome Research 14 (February 2015) 587 – 602. DOI: 10.1021/pr500966h

  9. HK Ho, JCY Chan, KD Hardy and ECY Chan. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metabolism Review 47 (February 2015) 21 – 28. DOI: 10.3109 Special Edition Dedicated to Sid Nelson’s Contributions to the Field of Drug Metabolism.

  10. KL Chang, HN Pee, WP Tan, GS Dawe, E Holmes, JK Nicholson, ECY Chan and PC Ho*. Metabolic profiling of CHO-AßPP695 cells revealed mitochondrial dysfunction prior to Aß pathology and potential therapeutic effects of both PPARγ and PPARα agonisms for Alzheimer’s disease. Journal of Alzheimer’s Disease 44 (January 2015) 215 – 231. DOI: 10.3233/JAD-140429

  11. LC Phua, XP Chue, PK Koh, PY Cheah, ECY Chan* and HK Ho*. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians. Oncology Reports 32 (May 2014) 97 – 104. DOI: 10.3892/or.2014.3193

  12. LC Phua, XP Chue, PK Koh, PY Cheah, HK Ho* and ECY Chan*. Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biology & Therapy 15 (April 2014) 389 – 397. DOI: 10.4161/cbt.27625

  13. MD Damavandi, ECY Chan, JP Kraus, PC Ho and TS Kang*. Development of an UPLC-MS/MS method for assaying the enzymatic activity of propionyl coenzyme-A carboxylase. Bioanalysis 6 (February 2014) 335 – 348. DOI: 10.4155/bio.13.297

  14. P Bahety, YM Tan, Y Hong, L Zhang, ECY Chan* and PL Ee*. Metabotyping of docosahexaenoic acid – treated Alzheimer’s disease cell model. PLOS ONE (February 2014) DOI: 10.1371/journal.pone.0090123

  15. T Nema, ECY Chan and PC Ho*. Applications of monolithic materials for sample preparation. Journal of Pharmaceutical and Biomedical Analysis 87 (January 2014) 130 – 141. DOI: 10.1016/j.jpba.2013.05.036

  16. EA Bard-Chapeau, A Nguyen, AG Rust, A Sayadi, P Lee, BQ Chua, LS New, J de Jong, JM Ward, CKY Chin, V Chew, HC Toh, J Abastado, T Benoukraf, R Soong, FA Bard, AJ Dupuy, RL Johnson, GK Radda, ECY Chan, LFA Wessels, DJ Adams, NA Jenkins and NG Copeland*. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nature Genetics 46 (January 2014) 24 – 32. DOI: 10.1038/ng.2847

  17. LC Phua, PK Koh, PY Cheah, HK Ho* and ECY Chan*. Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces. Journal of Chromatography B 937 (October 2013) 103 – 113. DOI: 10.1016/j.jchromb.2013.08.025

  18. KK Pasikanti, K Esuvaranathan,Y Hong, PC Ho, R Mahendran, LRN Mani, E Chiong and ECY Chan*. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. Journal of Proteome Research 12 (September 2013) 3865 – 3873. DOI: 10.1021/pr4000448

  19. BD Prakash, K Esuvaranathan,PC Ho, KK Pasikanti, ECY Chan and CW Yap*. An automated Pearson’s correlation change classification (APC3) approach for GC/MS metabonomic data using total ion chromatogram (TIC). Analyst 138 (May 2013) 2883 – 2889. DOI: 10.1039/c3an00048f

  20. HH Cheong, J Masilamani, ECY Chan, SY Chan* and TT Phan*. Metabolically functional hepatocyte-like cells from human umbilical cord lining epithelial cells. Assay and Drug Development Technologies 11 (March 2013) 130  – 138. DOI: 10.1089/adt.2011.444

  21. LC Phua, M Mal, PK Koh, PY Cheah, ECY Chan* and HK Ho*. Investigating the roles of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. Cancer Chemotherapy and Pharmacology 71 (March 2013) 817 – 823. DOI: 10.1007/s00280-012-2054-0

  22. LS New, TP Lim, JW Oh, GJS Cheah, AL Kwa and ECY Chan*. Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated clearance of rifampicin. Analytical and Bioanalytical Chemistry 405 (January 2013) 1407 – 1415. DOI: 10.1007/s00216-012-6549-7

  23. ZP Hu, ER Browne, T Liu, TE Angel, PC Ho and ECY Chan*. Metabonomic profiling of TASTPM transgenic Alzheimer’s disease mouse model. Journal of Proteome Research 11 (December 2012) 5903 – 5913. DOI: 10.1021/pr300666p

  24. S Saha, DSZ Chan, CY Lee, W Wong, LS New, WK Chui, ECY Chan* and HK Ho*. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties. European Journal of Pharmacology 697 (December 2012) 13 – 23. DOI: 10.1016/j.ejphar.2012.09.021

  25. YL Teo, M Saetaew, S Chanthawong, YS Yap, ECY Chan, HK Ho and A Chan*. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Research and Treatment 133 (June 2012) 703 – 711. DOI: 10.1007/s10549-012-1995-7

  26. WPK Ching, SH Thng, AP Hui, DY Lee, ECY Chan* and YS Ho*. LC-MS-based metabolic characterization of high monoclonal antibody-producing chinese hamster ovary cells. Biotechnology and Bioengineering 109 (December 2012) 3103 – 3111. DOI: 10.1002/bit.24580

  27. ECY Chan*, LS New, TB Chua, CW Yap, HK Ho and SD Nelson. Interaction of lapatinib with cytochrome P450 3A5. Drug Metabolism & Disposition 40 (July 2012) 1414 – 1422. DOI: 10.1124/dmd.112.044958

  28. HT Chng, HK Ho, CW Yap, SH Lam and ECY Chan*. An investigation of the bioactivation potential and metabolism profile of zebrafish versus human. Journal of Biomolecular Screening 17 (August 2012) 974 – 986. DOI: 10.1177/1087057112447305.

  29. ECY Chan*. Thomas O. Metz (Ed.): Metabolic profiling. Methods and protocols. Analytical Bioanalytical Chemistry 403 (July 2012) 2465 – 2466. DOI: 10.1007/s00216-012-6079-3.

  30. M Mal, PK Koh, PY Cheah and ECY Chan*. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Analytical Bioanalytical Chemistry 403 (April 2012) 483 – 493. DOI: 10.1007/s00216-012-5870-5

  31. T Nema, ECY Chan and PC Ho*. Efficiency of a miniaturized silica monolithic cartridge in reducing matrix ions as demonstrated in the simultaneous extraction of morphine and codeine from urine samples for quantification with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Journal of Mass Spectrometry 46 (September 2011) 891 – 900. DOI: 10.1002/jms.1966.

  32. LY Chen, L Zhou*, ECY Chan*, J Neo and R Beuerman. Characterization of the human tear metabolome by LC-MS/MS. Journal of Proteome Research 10 (October 2011) 4876 – 4882. DOI: 10.1021/pr2004874.

  33. JCY Chan, LS New, HK Ho and ECY Chan*. Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation. Toxicology Letters 206 (October 2011) 314 – 324. DOI: 10.1016/j.toxlet.2011.07.019.

  34. KM Banday, KK Pasikanti, ECY Chan, R Singla, KVS Rao, VA Chauhan* and RK Nanda*. Use of urine volatile organic compounds could discriminate tuberculosis patients from healthy subjects. Analytical Chemistry 83 (2011) 5526 – 5534. DOI: 10.1021/ac200265g.

  35. ECY Chan*, KK Pasikanti and JK Nicholson. Global urinary metabolic profiling procedures using gas chromatography mass spectrometry. Nature Protocols 6 (October 2011) 1483 – 1499. DOI: 10.1038/nprot.2011.375.

  36. T Nema, ECY Chan and PC Ho*. Extraction of ketamine from urine using a miniature silica monolithic cartridge followed by quantification with liquid chromatography tandem mass spectrometry (LC-MS/MS). Journal of Separation Science 10 (2011) 2079 – 2087. DOI: 10.1002/jssc.201000922.

  37. KL Chang, LS New, M Mal, CW Goh, CC AW, ER Browne and ECY Chan*. Metabolic profiling of 3-nitroproprionic acid early-stage Huntington’s disease rat model using gas chromatography time-of-flight mass spectrometry. Journal of Proteome Research 10 (2011) 2079 – 2087. DOI: 10.1021/pr2000336. 

  38. H Takakusa, MD Wahlin, C Zhao, KL Hanson, LS New, ECY Chan and SD Nelson*. Metabolite intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metabolism & Disposition 39 (2011) 1022 – 1030. DOI: 10.1124/dmd.110.037531.

  39. H Sukardi, HT Chng, ECY Chan, Z Gong and SH Lam*. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. Expert Opinion on Drug Metabolism and Toxicology 7 (2011) 579 – 589. DOI: 10.1517/17425255.2011.562197.

  40. DF Toh, DN Patel, ECY Chan, A Yeo, SY Neo and HL Koh*. Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells. Chinese Medicine 6 (2011) 1 – 9.

  41. M Mal, PK Koh, PY Cheah and ECY Chan*. Ultra-pressuure liquid chromatography/tandam mass spectrometry targeted profiling of arachidonic acid and eicosanoids in human colorectal cancer. Rapid Communications in Mass Spectrometry 25 (2011) 755 – 764. DOI: 10.1002/rcm.4926.

  42. DJY Ng, KK Pasikanti and ECY Chan*. Trend analysis of metabonomics and systemic review of metabonomics-derived cancer marker metabolites. Metabolomics 7 (2011) 155 – 178. DOI: 10.1007/s11306-010-0250-7.

  43. YT Koh, KK Pasikanti, CW Yap* and ECY Chan*. Comparative evaluation of software for retention time alignment of gas chromatography/time-of-flight mass spectrometry-based metabonomic data. Journal of Chromatography A 1217 (2010) 8308 – 8316. DOI: 10.1016/j.chroma.2010.10.101.

  44. KK Pasikanti, J Norasmara, S Cai, R Mahendran, K Esuvaranathan, PC Ho and ECY Chan*. Metabolic footprinting of tumorigenic and non-tumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry. Analytical and Bioanalytical Chemistry 398 (2010) 1285 – 1293. DOI: 10.1007/s00216-010-4055-3.

  45. WC Teng, JW Oh, LS New, MD Wahlin, SD Nelson, HK Ho and ECY Chan*. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Molecular Pharmacology 78 (2010) 693 – 703. DOI: 10.1124/mol.110.065839.

  46. T Nema, ECY Chan and PC Ho*. Application of silica based monolith as solid phase extraction cartridge for extracting polar compounds from urine. Talanta 82 (2010) 488 – 494. DOI: 10.1016/j.talanta.2010.04.063.

  47. X Ma and ECY Chan*. On-line chromatographic screening of matrix metalloproteinase inhibitors using immobilized MMP-9 enzyme reactor. Journal of Chromatography B 878 (2010) 1777 – 1783. DOI: 10.1016/j.jchromb.2010.04.040.

  48. KK Pasikanti, K Esuvaranathan, PC Ho, R Mahendran, R Kamaraj, QH Wu, E Chiong and ECY Chan*. Noninvasive urinary metabonomic diagnosis of human bladder cancer. Journal of Proteome Research 9 (2010) 2988 – 2995. DOI: 10.1021/pr901173v.

  49. S Saha, LS New, HK Ho, WK Chui, ECY Chan*. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes. Toxicology Letters 195 (2010) 135 – 141. DOI: 10.1016/j.toxlet.2010.03.010.

  50. DF Toh, LS New, HL Koh* and ECY Chan*. Ultra-high performance liquid chromatography / time-of-flight mass spectrometry (UHPLC/TOFMS) for time-dependent profiling of raw and steamed Panax notoginseng. Journal of Pharmaceutical and Biomedical Analysis 52 (2010) 43 – 50. DOI: 10.1016/j.jpba.2009.12.005. 

  51. S Saha, LS New, HK Ho, WK Chui and ECY Chan*. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicology Letters 192 (2010) 141 – 149. DOI: 10.1016/j.toxlet.2009.10.014.

  52. X Ma and ECY Chan*. Fluorescence-based liver microsomal assay for screening of pharmaceutical reactive metabolites using glutathione conjugated 96-well plates. Bioconjugate Chemistry 21 (2010) 46 – 55. DOI: 10.1021/bc900289m.

  53. HT Chng, LS New, AH Neo, CW Goh, ER Browne and ECY Chan*. A sensitive LC/MS/MS bioanalysis assay of orally-administered lipoic acid in rat blood and brain tissue. Journal of Pharmaceutical and Biomedical Analysis 51 (2010) 754 – 757. DOI: 10.1016/j.jpba.2009.09.028.

2009- 1998

  1. DPQ Goh, AH Neo, CW Goh, CC Aw, LS New, WS Chen, Z Atcha, ER Browne and ECY Chan*. Metabolic Profiling of Rat Brain and Cognitive Behavioral Tasks: Potential Complementary Strategies in Preclinical Cognition Enhancement Research. Journal of Proteome Research 8 (2009) 5679 – 5690. DOI: 10.1021/pr900795g.

  2. R  Kashimshetty, VG Desai, VM Kale, T Lee, CL Moland, WS Branham, LS New, ECY Chan, H Younis and UA Boelsterli*. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicology and Applied Pharmacology 238 (2009) 150 – 159. DOI: 10.1016/j.taap.2009.05.007.

  3. M Mal, PK Koh, PY Cheah and ECY Chan*. Development and validation of a gas chromatography mass spectrometry (GC/MS) method for the metabolic profiling of human colon tissue. Rapid Communications in Mass Spectrometry 23 (2009) 487 – 494. DOI: 10.1002/rcm.3898.

  4. ECY Chan*, LS New, CW Yap and LT Goh. Pharmaceutical metabolite profiling using quadrupole/ ion mobility spectrometry/ time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry 23 (2009) 384 – 394. DOI: 10.1002/rcm.3887.

  5. ECY Chan*, PK Koh, M Mal, PY Cheah, KW Eu, A Backshall, R Cavill, JK Nicholson and H Keun. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). Journal of Proteome Research 8 (2009) 351 – 361. DOI: 10.1021/pr8006232.

  6. HT Chng, LS New, AH Neo, CW Goh, ER Browne and ECY Chan*. Distribution study of orally administered lipoic acid in rat brain tissues. Brain Research 1251 (2009) 80 – 86. DOI: 10.1016/j.brainres.2008.11.025.

  7. KK Pasikanti, PC Ho and ECY Chan*. Development and validation of a GC/MS metabonomic platform for the global profiling of urinary metabolites. Rapid Communications in Mass Spectrometry 22 (2008) 2984 – 2992. DOI: 10.1002/rcm.3699.

  8. LC Phua, LS New, CW Goh, AH Neo, ER Browne and ECY Chan*. Investigation of the drug-drug Interaction between α-lipoic acid and valproate via mitochondrial β-oxidation. Pharmaceutical Research 25 (2008) 2639 – 2649. DOI: 10.1007/s11095-008-9681-5.

  9. WS Law, PY Huang, ES Ong*, CN Ong, SFY Li, KK Pasikanti, ECY Chan. Metabonomics investigation of human urine after ingestion of green tea with gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry and 1H NMR spectroscopy. Rapid Communications in Mass Spectrometry 22 (2008) 2436 – 2446. DOI: 10.1002/rcm.3629.

  10. SC Tan, LS New and ECY Chan*. Prevention of acetaminophen (APAP) induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine. Toxicology Letters 180 (2008) 174 – 81. DOI: 10.1016/j.toxlet.2008.06.001.

  11. QM Seah, LS New, ECY Chan, UA Boelsterli*. Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77-1726. Drug Metabolism Letters 2 (2008) 153 – 57. DOI: 10.2174/187231208785425791.

  12. KK Pasikanti, PC Ho and ECY Chan*. Gas Chromatography/Mass Spectrometry in Metabolic Profiling of Biological Fluids. Journal of Chromatography B 871 (2008) 202 – 211. DOI: 10.1016/j.jchromb.2008.04.033.  Top 25 Most Cited Review Article (2008-2009).

  13. LS New and ECY Chan*. Evaluation of BEH C18, BEH HILIC and HSS T3 (C18) Column Chemistries for the UPLC/MS/MS Analysis of Glutathione, Glutathione Disulfide and Ophthalmic Acid in Mouse Liver and Human Plasma.  Journal of Chromatographic Science 48 (2008) 209 – 214. DOI: 10.1093/chromsci/46.3.209. Special UPLC Issue

  14. ECY Chan* and LS New. In vitro metabolism of leflunomide by mouse and human liver microsomes. Drug Metabolism Letters 1 (2007) 299 – 305. DOI: 10.2174/187231207783221402.

  15. LS New, S Saha, MMK Ong, UA Boelsterli and ECY Chan*. Pharmacokinetic study of intraperitoneal administered troglitazone in mice using UPLC/MS/MS. Rapid Communications in Mass Spectrometry 21 (2007) 982 – 988. DOI: 10.1002/rcm.2924.

  16. ECY Chan*, SL Yap, AJ Lau, PC Leow, DF Toh and HL Koh. UPLC/TOFMS based metabolomics of raw and steamed Panax notoginseng. Rapid Communications in Mass Spectrometry 21 (2007) 519 – 528. DOI: 10.1002/rcm.2864.

  17. HL Koh*, AJ Lau and ECY Chan.  Hydrophilic interaction liquid chromatography with tandem mass spectrometry for the determination of underivatized dencichine (b-N-oxalyl-L-a,b-diaminopropionic acid) in Panax medicinal plant species. Rapid Communications in Mass Spectrometry 9 ( 2005) 1237 -1 244. DOI: 10.1002/rcm.1928.

  18. ECY Chan*, TW Lee, PC Ho and LJ Fang. Modeling Caco-2 permeability of drugs using immobilized artificial membrane chromatography and physicochemical descriptors. Journal of Chromatography A 1072 (2005) 159 – 168. DOI: 10.1016/j.chroma.2005.03.006.

  19. L Bo and ECY Chan*. Application of visual basic in high-throughput mass spectrometry-directed purification of combinatorial libraries. Journal of Combinatorial Chemistry 5 (2003) 834 – 841. DOI: 10.1021/cc030032t.

  20. ECY Chan and PC Ho*. Preparation and characterization of immunogens for antibody production against metanephrine and normetanephrine. Journal of Immunological Methods 266 (2002) 143 – 154. DOI: 10.1016/s0022-1759(02)00143-6.

  21. ECY Chan*, AW Wang, WP Jia and GD Dollinger. An automated LC method for the small-scale purification of organic molecules derived from combinatorial libraries. Journal of Pharmaceutical and Biomedical Analysis 29 (2002) 139 – 146. DOI: 10.1016/s0731-7085(02)00044-4.

  22. ECY Chan and PC Ho*. High-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometric method for the analysis of catecholamines and metanephrines in human urine. Rapid Communications in Mass Spectrometry 14 (2000) 1959 – 1964. DOI: 10.1002/1097-0231(20001115)14:21<1959::AID-RCM117>3.0.CO;2-T.

  23. ECY Chan, PY Wee, PY Ho and PC Ho*. High-performance liquid chromatographic assay for catecholamines and metanephrines using fluorimetric detection with pre-column 9-fluorenylmethyloxycarbonyl chloride derivatization. Journal of Chromatography B 749 (2000) 179 – 189. DOI: 10.1016/s0378-4347(00)00423-0.

  24. ECY Chan, PY Wee and PC Ho*. Evaluation of degradation of urinary catecholamines and metanephrines and deconjugation of their sulfoconjugates using stability-indicating reversed-phase ion-pair HPLC with electrochemical detection. Journal of Pharmaceutical and Biomedical Analysis 22 (2000) 515 – 526. DOI: 10.1016/s0731-7085(99)00308-8.

  25. ECY Chan, PY Wee and PC Ho*. The value of analytical assays that are stability-indicating. Clinica Chimica Acta 288 (1999) 47 – 53. DOI: 10.1016/s0009-8981(99)00137-0.

  26. ECY Chan and PC Ho*. Enantiomeric separation of tramadol hydrochloride and its metabolites by cyclodextrin-mediated capillary zone electrophoresis. Journal of Chromatography B 707 (1998) 287 – 294. DOI: 10.1016/s0378-4347(97)00605-1.

Invited Editorial/Commentary

  1. JWH Leow and ECY Chan. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: a focus on substrate inhibition. Biochemical Pharmacology 169 (November 2019)  113615 DOI: 10.1016/j.bcp.2019.08.017.

  2. A Karkhanis, Y Hong and ECY Chan*. Inhibition and iinactivation of human CYP2J2:  Implications in cardiac pathophysiology and  opportunities in cancer therapy. Biochemical Pharmacology 135 (July 2017) 12-21 DOI: 10.1016/j.bcp.2017.02.017.

  3. Y Hong, K Esuvaranathan, KK Pasikanti and ECY Chan*. Metabonomic diagnosis of bladder cancer – what are the advantages and considerations? Bioanalysis 7 (November 2015) 2727-2729 DOI: 10.4155/bio.15.192

 

Book Chapters

  1. Z Wang, EYQ Leow, HY Moy and ECY Chan*. Advances in urinary biomarker research of synthetic cannabinoids. Advances in Clinical Chemistry (April 2023) 1-32 DOI: 10.1016/bs.acc.2023.03.004

  2. JWH Leow, LWT Tang and ECY Chan*. Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology. In: Pharmacology and Toxicology of Cytochrome P450 – 60th Anniversary. Ed. Hiroshi Yamazaki. Advances in Pharmacology. 95 (August 2022) 131-176 DOI: 10.1016/bs.apha.2022.05.003

  3. SH Lee, M Mal and KK Pasikanti and ECY Chan*. Gas Chromatographic Applications in Metabolomics. In: Gas Chromatography Second Edition. Ed. CF Poole. Elsevier  (April 2021) 727 – 743 DOI:10.1016/B978-0-12-820675-1.00004-6.

  4. LY Yip and ECY Chan*. Gas Chromatography/Mass spectromerty-Based Metabonomics. In: Proteomic and Metabolomic Approaches to Biomarker Discovery. Ed. TD Veenstra and HJ Issaq. Elsevier (June 2013) 131 – 144 DOI: 10.1016/B978-0-12-394446-7.00008-X.

  5. ECY Chan*, M Mal and KK Pasikanti. Metabonomics. In: Gas Chromatography. Ed. CF Poole. Elsevier (June 2012) 545 – 562 DOI: 10.1016/B978-0-12-385540-4.00024-9.

  6. PC Ho and ECY Chan. Chromatographic Measurement of Catecholamines and Metanephrines. In: Chromatographic Methods in Clinical Chemistry and Toxicology. Ed. RL Berholf and RE Winecker. John Wiley & Sons, Ltd. (March 2007) 101 -126 DOI: 10.1002/9780470023129.ch7.

 

Media Coverage

  1. 本地科研找出生物标志物 侦测新型合成大麻素. 王康威. 早报，11月29日 2022

  2. 国大药剂系团队研发更安全心房颤动药物. 王康威. 早报，7月18日 2022

  3. 国大研发生物合成代谢物 可助执法人员侦测毒品滥用概况. 王康威. 早报，8月30日 2021 

  4. NUS researchers find a new method to detect designer drug abuse. Cheryl Tan. The Straits Time, 30 August 2021

  5. A new way to detect consumers of illicit drugs. Cheryl Tan. The Straits Time, 01 February 2021, Science, pD11.

  6. Repurposing drugs for treatment of Covid-19. Eric Chan. The Straits Time, 13 June 2020, ScienceTalk, pD7.

  7. Virtual patients for therapeutic drug trials. Eric Chan and Eleanor Cheong. The Straits Time, 13 September 2018, ScienceTalk, pB9.

  8. Painless, cheaper way to diagnose bladder cancer. Judith Tan. The Straits Time, 22 May 2010, Science, pD10.

 

bottom of page